PCSK9 and Hypercholesterolemia: The observed degree of base editing at this Pcsk9 splice donor with v4 BE-eVLPs (>60%) is thought to be sufficient for the reduction of serum LDL and treatment of hypercholesterolemia (Musunuru et al., 2021).